Abstract:Introduction: Candida albicans is the primary cause of systemic candidiasis, which is involved in high morbidity and mortality. Drug resistance exacerbates these problems. In addition, there are limited antifungal drugs available. In order to solve these problems, combination therapy has aroused great interest. Teriflunomide is an immunosuppressant. In the present work, we aimed to identify whether teriflunomide can reverse the resistance of Candida albicans in the presence of sub-inhibitory concentrations of fluconazole in vitro and in vivo. Methods: Seven Candida albicans isolates were used in this study. Susceptibility of Candida albicans in vitro to the drugs was determined using a checkerboard microdilution assay in accordance with the recommendations of the Clinical and Laboratory Standards Institute. The effects of drugs on biofilm biomass of Candida albicans were determined by crystal violet staining. The development ability of Candida albicans hyphae was performed using a modified broth microdilution method. Galleria mellonella was used for testing the in vivo efficacy of the combination therapies. Results: We found that the combination of teriflunomide (64 µg/mL) and fluconazole (0.5-1 µg/mL) has a significant synergistic effect in all resistant Candida albicans isolates (n=4). Also, this drug combination could inhibit the immature biofilm biomass and hyphae formation of resistant Candida albicans. Galleria mellonella was used for testing the in vivo efficacy of this combination therapies. As for the Galleria mellonella larvae infected by resistant Candida albicans, teriflunomide (1.6 µg/larvae) combined with fluconazole (1.6 µg/larvae) significantly increased their survival rates, and reduced the fungal burden, as well as damage of tissue in comparison to that in the control group or drug monotherapy group. Conclusion: These results expand our knowledge about the antifungal potential of teriflunomide as an adjuvant of existing antifungal drugs, and also open new perspectives in the treatment of resistant Candida albicans based on repurposing clinically available nonantifungal drugs.

Synergistic effect of mangiferin in combination with fluconazole against fluconazole-resistant Candida albicans

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

The low-affinity receptor for IgE (FcεRII or CD23) as a therapeutic target

The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans

Mangiferin potentiates the activity of antifungal agents against fluconazole-resistant Candida spp

The Effect of Ginkgolide B Combined with Fluconazole Against Drug-Resistant Candida Albicans Based on Common Resistance Mechanisms

Synergistic Effect of Berberine Hydrochloride and Fluconazole Against Candida albicans Resistant Isolates

Fungus-mediated Biosynthesis of Gold Nanoparticles with Synergistic Antifungal Activity Against Multidrug-Resistant Candida Albicans

Interactions of Cephradine and Cefaclor with the Intestinal Absorption of D‐Galactose

The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans

Synergistic potential of teriflunomide with fluconazole against resistant Candida albicans in vitro and in vivo

Mechanism and bioinformatics analysis of the effect of berberine-enhanced fluconazole against drug-resistant Candida albicans

In vitro and in vivo analysis of monotherapy and dual therapy with ethyl caffeate and fluconazole on virulence factors of Candida albicans and systemic candidiasis

Candida albicans targets that potentially synergize with fluconazole

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans: Synergy of PAB and FLC against Candida albicans

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Identification of novel membrane structures in Plasmodium falciparum infected erythrocytes.

Fluconazole Inhibits Cellular Ergosterol Synthesis to Confer Synergism with Berberine Against Yeast Cells.

Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of Candida species.

Antifungal Activity and Potential Mechanism of 6,7, 4′-O-Triacetylscutellarein Combined With Fluconazole Against Drug-Resistant C. albicans